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Subjective well-being (v. Zerssen scale) improved during
RT from 15.7  8 to 11.8  8 (p  0.001).
CONCLUSION: Alterable cardiovascular risk factors
and subjective quality of life are significantly improved
by health training and treatment during standardized car-
diac inpatient rehabilitation therapy. Follow-up studies
are needed to assess the long-term course and to improve
preventive strategies.
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OBJECTIVE: Within the Pistoia Project (PP), a large
screening study whose objective is the identification of
hypertensive disease, organ damage, and related risk fac-
tors to activate actions of primary and secondary preven-
tion, we conducted a preliminary cost of illness analysis
to investigate if age, gender, and/or severity of hyperten-
sion could influence the use of healthcare services and
therefore have a direct impact on costs.
METHODS: Forty-five patients’ records were randomly
selected from the GP’s screening forms of the PP: patients
were either hypertensive or normotensive under treat-
ment. Using healthcare codes, we computed hospital data
(DRG code and cost), while pharmaceutical consumption
(units and cost) was retrieved from the pharmaceutical re-
gional database. The local Hypertension Centre retrieved
number and typology of specialist consultations and pro-
cedures. Indirect costs were partly calculated from social
security system certificates, and partly estimated under
the hypothesis that each hospital stay and each specialist
visits imply a loss of working days.
RESULTS: In 1997, 45 patients generated a total cost of
Lit. 29.9 million, with an average cost per patient per
year of Lit. 664,282. Pharmaceutical care accounted for
45% of total cost, followed by hospital admissions
(34%), productivity losses (16.4%), and specialist visits
and procedures (4.3%). 
CONCLUSIONS: This preliminary analysis has demon-
strated the potential of such an instrument to evaluate the
cost of managing hypertension in a large area as the Pis-
toia province. Further research is needed on larger sam-
ples to identify patterns of resource use and to evaluate
the influence of illness severity on the total cost of this
disease.
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OBJECTIVE: To estimate the economic value of the 4F
catheter relative to the 6F in diagnostic coronary angiog-
raphy.
METHODS: A decision tree model was developed, based
on German practice patterns and costs. Expected total
costs of diagnostic coronary angiography using 4F and 6F
catheters in both the ambulatory and inpatient settings
were calculated and compared, together with measures of
procedure success. Costs include the costs of catheters,
contrast media, time in clinic, professional services, and
costs to treat complications. Measures of procedure suc-
cess, as observed in trials of 4F versus 6F, include fluoros-
copy, procedure, compression, and immobilization times;
complication rates; and catheter exchange rates. Complica-
tion rates are those observed in two large German observa-
tional studies. 
RESULTS: In the base-case scenario, the 4F catheter
saves an average of 22 DM per procedure, despite a
higher list price. These savings derive primarily from re-
duced need for contrast media. The 4F is associated with
fewer complications; however, because of the low overall
complication rate, the associated savings are minor.
Given a lower likelihood of bleeding complications, the
4F may enable more procedures to be performed in the
ambulatory setting. Assuming a modest increase in the
proportion of ambulatory procedures results in an addi-
tional savings of 10 DM per procedure.
CONCLUSION: Compared to the 6F catheter, the 4F is
estimated to save an average of 22 DM per diagnostic
coronary angiography because of a reduced need for con-
trast media and a lower complication rate. If the 4F cath-
eter enables more procedures to be performed on an out-
patient basis, the potential cost savings increase.
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Admission (%) Discharge (%)
Arterial BP 140/90 mmHg 24 ** 8
Smoking 39 ** 5
Cholesterol 250 mg/dl 20 ** 5
LDL cholesterol 100 mg/dl 87 ** 67
LDL/HDL cholesterol 2.5 86 ** 70
Triglycerides 200 mg/dl 22 * 15
Glucose 140 mg/dl 14 ns 11
BMI 30 kg/m2 18 * 15
* p  0.01, ** p  0.001, ns  not significant.
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OBJECTIVE: Quality of life is not well studied in atrial
fibrillation (AF), the most prevalent rhythm disturbance
with significant impact on morbidity and mortality. We
report the development of a brief disease-specific QoL in-
strument for use in clinical trials, surveillance studies, and
clinical practice.
METHODS: Fifty-one items, based on literature, patient
focus groups, and a cardiology expert panel were admin-
istered via telephone interview to 73 chronic AF and 23
congestive heart failure (CHF), along with 25 angina con-
trol patients. 
RESULTS: Item reduction techniques produced the 20-item
AFIS comprising four symptom scales (dyspnea, fatigue, pal-
pitations syncope: 11 items) and three QoL scores measur-
ing functional, social and emotional impact (9 items). Inter-
nal consistencies were acceptable for all symptom scales
(Cronbach  0.73–0.77) and the QoL scales (Cronbach 
0.74–0.92). AFIS Total Symptom Impact (SI) score ex-
plained 50% of the variation in each QoL impact score
(R2  0.49 [functional], 0.44 [emotional], 0.55 [social]) and
75% (R2  0.74) of the total QoL impact (QI) score. We
identified two symptom impact (SI) threshold scores: mod-
erate AF impact (SI  40; sensitivity 0.86, 1-specificity 0.92)
and major AF impact (SI  60; sensitivity 0.96, 1-specificity
0.98). Mild symptomatic CAF patients (SI  40) reported
little QoL interference. Moderate symptomatic and major
symptomatic CAF patients had QI scores 200% and 665%
worse than the mild CAF patients. SI scores accounted for
50% (R2  0.50) and nearly 25% (R2  0.22) of total QI
variation in CHF and angina patients, respectively.
CONCLUSION: Mild AF symptoms are well tolerated.
However, moderate symptom impact (over 50% of pa-
tients) doubles the interference with QoL; while major
impact (33% of patients) approached a seven-fold wors-
ening of QoL. The Atrial Fibrillation Impact Scale ap-
pears to be a useful tool for predicting worsening QoL
among atrial fibrillation patients and for informing treat-
ment decisions.
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OBJECTIVE: With the increase of QoL assessment in
clinical trials, it is necessary to have cross-culturally valid
instruments to pool data across countries.
METHODS: The SAQ, a 19-item instrument designed in
US English, assesses five domains of coronary artery dis-
ease. Prior to use in an international trial, the original
had to undergo cultural adaptation, giving rise to 11 lan-
guage versions and a modified original. The cultural ad-
aptation process involved the recruitment of a QoL spe-
cialist in each country. Native speakers produced two
independent forward translations. These were reconciled
and back-translated into English. The translations were
tested for comprehension in a sample target population,
compared and internationally harmonized. The developer
of the SAQ clarified concepts underlying each item.
RESULTS: Translation problems involved finding con-
ceptual equivalents of typical US expressions and con-
structions and translating the original response catego-
ries. Examples for which a rationale of translation choice
and modification to the original will be discussed, are the
following: although activities such as “showering” and
“swimming” are less common outside the US, satisfac-
tory equivalents were found. The translation of “how sat-
isfied are you that everything is being done. . .,” however,
had to be rendered as “how convinced are you. . . .” It
was impossible to reproduce the original response scale
referring to “very, moderately, somewhat, a little, not at
all.” Equivalent answers in the translation had to refer to
“extremely, quite a bit, moderately, slightly, not at all.”
For reasons of comparability, the original was changed
accordingly. 
CONCLUSIONS: Before use in an international trial, rig-
orous cultural adaptation was essential to producing
cross-culturally valid language versions of the SAQ. This
process, entailing modifications to an already validated
original, might make further validation necessary. Fur-
ther responsiveness data will be generated by the clinical
trial. Ideally, initial instrument design should include in-
ternational input.
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OBJECTIVES: An analysis is being carried out to assess
the impact of clinical parameters, over and above the
treatment effect, in an evaluation of coronary heart dis-
ease (CHD) in German males.
METHODS: This analysis is part of a study which uses the
Coronary Heart Disease Risk Assessment Model (CHD
RAM), a decision analytical model, to evaluate the cost-
effectiveness of cholesterol-lowering agents for the primary
prevention of CHD in German males. Although the wider
study considers data for men in eight 5-year age groups
ranging from 35–39 to 70–74 years, the clinical sensitivity
analysis focuses on the 50–55 age group for three doses of
cerivastatin, a cholesterol-lowering agent. Baseline data
were primarily obtained from the published literature and
expert opinion. The clinical parameters—compliance rate
profiles, smoking behaviour, mean body mass index and
systolic blood pressure—will be assessed in terms of their
impact on CHD risk and life years gained. This will be esti-
